Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2005 057 488.3 |
96 | EP file number | EAKZ | 20 20 0642.5 |
97 | EP publication number | EPN | 3805248 |
54 | Designation/title | TI | PROZESS, UM ANTIKÖRPER UND THERAPEUTISCHE PRODUKTE ZU KONZENTRIEREN |
51 | IPC main class | ICM (ICMV) | C07K 1/34 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 39/395 (2006.01) |
22 | DE application date | DAT | Sep 8, 2005 |
96 | EP application date | EAT | Sep 8, 2005 |
43 | Date of first publication | OT | Apr 14, 2021 |
| Date of publication of grant | PET | Jan 18, 2023 |
71/73 | Applicant/owner | INH | GENENTECH, INC., South San Francisco, CA, US; Novartis AG, Basel, CH |
72 | Inventor | IN | Winter, Charles Matthew, Belmont, CA 94002, US |
| Address for service | | Genentech, Inc., SOUTH SAN FRANCISCO, CA 94080-4990, US |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 609092 P Sep 9, 2004
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 220362 Sep 6, 2005
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003805248A2 Searchable text:
EP000003805248A2 Original document:
EP000003805248B1 Searchable text:
EP000003805248B1 |
43 | Date of first publication | EVT | Apr 14, 2021 |
| Date of the first transfer into DPMAregister | EREGT | Apr 14, 2021 |
| Date of the (most recent) update in DPMAregister | REGT | Aug 28, 2024 (Show all update days)(Hide all update days)- Aug 28, 2024
- Jun 6, 2024; Nov 30, 2023; Oct 26, 2023; Sep 14, 2023; Jan 26, 2023; Dec 22, 2022
- Historical data not available for this/these date(s)
- Apr 14, 2021
- Date of the first transfer into DPMAregister
|